Labetalol
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Beta Blockers | Labetalol | 100-400 mg Q12H | Administer Anytime During HD; Post HD if Hypotensive |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 328 | <5 | 3-9 | 12.9 | 50 | 3.3-7.9 | 30.67 | <1 (low flux) |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00598
- Halstenson C, Opsahl J, Pence T, et al. The disposition and dynamics of labetalol in patients on dialysis. Clinical pharmacology and therapeutics. 1986;40(4):462-8.
- Inrig J. Antihypertensive agents in hemodialysis patients: a current perspective. Seminars in dialysis. 2010;23(3):290-7.